Company news

Ovid Therapeutics Inc. news in 2025

Ovid Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.

View company

Ovid Therapeutics Reports Phase 1 results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2, OV350 Intravenous

December 19, 2025

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

December 18, 2025

Ovid Therapeutics Appoints Dr. Petra Kaufmann as Chief Medical Officer

December 2, 2025

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

November 12, 2025

QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer

November 10, 2025

Ovid Therapeutics Announces Pricing of Private Placement Totaling up to $175 Million in Gross Proceeds

October 3, 2025

Ovid announces positive topline results for the next-generation GABA-aminotransferase inhibitor, OV329, that demonstrate strong inhibitory activity and a potential best-in-category safety profile

October 3, 2025

Ovid Therapeutics Reports Business Updates and Second Quarter 2025 Financial Results

August 13, 2025

Ovid Therapeutics to Participate in the BTIG Virtual Biotech Conference

July 23, 2025

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties

June 25, 2025

Ovid Therapeutics to Host Investor and Media Event Thursday, June 12, 2025

June 5, 2025

Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results

May 13, 2025

Ovid Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

April 2, 2025

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results

March 11, 2025

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors

March 3, 2025

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

February 27, 2025

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

February 4, 2025

Decks in 2025